Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$454.4B
1,767M shares
52-week range
$190.75 – $267.47
93% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
P/S (TTM)
7.2
EV / FCF (TTM)
26.8
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
www.abbvie.comNo one on the platform currently holds ABBV.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 928,071 | $214.9M |
| Bridgewater Associatesas of 2026-03-31 | 30,362 | $6.6M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-10-15 | $1.7300 | 2026-11-16 |
| 2026-07-15 | $1.7300 | 2026-08-14 |
| 2026-04-15 | $1.7300 | 2026-05-15 |
| 2026-01-16 | $1.7300 | 2026-02-17 |
| 2025-10-15 | $1.6400 | 2025-11-14 |
| 2025-07-15 | $1.6400 | 2025-08-15 |
| 2025-04-15 | $1.6400 | 2025-05-15 |
| 2025-01-15 | $1.6400 | 2025-02-14 |
| 2024-10-15 | $1.5500 | 2024-11-15 |
| 2024-07-15 | $1.5500 | 2024-08-15 |
No one on the platform has traded ABBV yet.
| 2024-04-12 | $1.5500 | 2024-05-15 |
| 2024-01-12 | $1.5500 | 2024-02-15 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 21.3% | 19.2% | 24.4% | — | — | — |
| Rev. Growth % | 8.6% | 6.0% | ||||
| Profit Margin % | 6.9% | 12.9% | 15.8% | |||
| Free Cash Flow Margin % | 29.1% | 36.5% | 35.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +5.1% on the P/E track.
At today's price, your expected annual return is +10.1% on the P/E track.
At today's price, your expected annual return is +14.4% on the P/E track.
Also held through funds
2 more books hold ABBV indirectly · VTI 0.6% of fund, AVUS 0.4% of fund
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $67.6B | +10.9% | $14.05 | $13.90–$14.54 | 18.6× | 15 |
| 2027 | $73.4B | +8.6% | $16.37 | $15.41–$17.62 | 16.0× | 14 |
| 2028 | $78.7B | +7.2% | $17.92 | $15.33–$21.34 | 14.6× | 9 |
| 2029 | $83.3B | +5.8% | $19.80 | $19.20–$20.23 | 13.2× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $3.61 | $3.65 | +1.1% |
| 2026-04-29 | $2.59 | $2.65 | +2.3% |
| 2026-02-04 | $2.65 | $2.71 | +2.3% |
| 2025-10-31 | $1.77 | $1.86 | +5.1% |
| 2025-07-31 | $2.88 | $2.97 | +3.1% |
| 2025-04-25 | $2.38 | $2.46 | +3.4% |
| 2025-01-31 | $2.98 | $2.16 | -27.5% |
| 2024-10-30 | $2.92 |
| $3.00 |
| +2.7% |
| $645.0B |
| — |
| MRKMerck & Co., Inc. | $145.34 | +0.98% | $359.0B | — |
| NVONovo Nordisk A/S | $43.48 | +0.95% | $193.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$OTLK $REGN $NVS $ABBV When the #Bollingerbands #squeeze, the #market is about to?
View on StockTwits ↗
$OSTX $SLS Very Subtle But Valuable Fact: Gps Ph1/2 MOS 18.4 Months for PR/ROC was longer than the FDA Approved Elahere 16.46 months that $ABBV Paid $10B for, but a SUBTLE distinction is the Patient Setting. GPS Key patients: Measurable Advanced Platinum Resistant Ovarian cancer --- vs $MRNA Melanoma Patients post surgery / semi remission State ... You can read the Conclusions of this GPS Phase 2 Data -- again Extended Survival -Correlated with Immune Response - Like all Gps trials. https://www.reddit.com/media?url=https%3A%2F%2Fpreview.redd.it%2Fgps-keytruda-phase-2-results-for-platinum-resistant-ovarian-v0-p3n52qpjmcph1.png%3Fwidth%3D2810%26format%3Dpng%26auto%3Dwebp%26s%3D24ce0c232be1ebd6148bb30c888a88c0847f1576
View on StockTwits ↗
$ABBV $JNJ $ABT taking some profits.... Fed's coming wed... and it won't be good news for bulls !!
View on StockTwits ↗$SLS This current short rigged $2.3B Market cap isn't even Close to What Gps is worth the moment the Imminent Phase 3 Results are Announced. $MRNA added $40B in a day for a Reason $RVMD added Nearly $30B the day its P3 results were announced. reddit.com/r/sellasLifescience $ABBV and $BMY who own Aza VEN know It ain't BAT Causing the Miraculous Survival.
View on StockTwits ↗$SLS $ABBV $BMY BAT for the SLS Control arm Failed 3 Aml remission maintenance trials. what do you think that means? Viale-M Failed in First Remission Viale-T Failed in post Transplant Maintenance Viale C and Verona - Failed
View on StockTwits ↗$SLS $ABBV $BMY Viale-M, T and C Failed
View on StockTwits ↗$SLS The $ABBV $BMY People Know its GPs. This current short rigged $2.3B Market cap isn't even Close to What is Gps is worth the moment the Imminent Phase 3 Results are Announced. $MRNA added $40B in a day for a Reason $RVMD added Nearly $30B the day its P3 results were announced. https://www.reddit.com/r/sellasLifescience/comments/1weo6k2/comment/p9fbhtj/?screen_view_count=1
View on StockTwits ↗$SLS at 60 events the IDMC UNBLINDED ACTUAL PHASE 3 MOS and IMMUNE RESPONSE DATA! Unblinded Actual Median Overall Survival and Immune Response data from the ongoing P3. $ABBV $BMY Own BAT - they all Know Gps is doing what its done in all 7 prior trials, including 2 Phase 2’s for AML REMISSION MAINTENANCE. and Yes BAT Failed 3 large P3’s and 2 for AML MAINTENANCE - Viale-M - Viale-T FAILED.
View on StockTwits ↗
$SLS $JNJ $MRK $ABBV September is recognized worldwide as Blood Cancer Awareness Month and Leukemia and Lymphoma Awareness Month, which includes bringing attention to AML. This month, as we reve in the stock price volatility and FOMO frenzy in an anticipation of REGAL '80th event', may we also take a few moments to remember the 80th 'event' is the end of someone's human life? Assuming REGAL success -- I hope the IDMC / FDA / Company would honor the life of this 'event' and all 79 events before, by expediting REGAL FA and the Accelerated Approval process. I'm sure all 80 events would want it that way.
View on StockTwits ↗
$ABBV People will always get sick and the need for medicine will never stop.
View on StockTwits ↗@Nmd_1980 @Londonplay who said anything about "immediately"? Come back and revisit your valuation once REGAL FA is published and 009 AML frontline study is successfully completed. Recall that $ABBV paid over $21 billion for Pharmacyclics' Imbruvica and its ADC IP assets -- over a decade ago. It's now almost 2027 and the competitive dynamics between the largest BPs is even more intense now, especially given many legacy drug patents set to expire over the next few years.
View on StockTwits ↗
$ABBV anyone wanting another read of this stock, check me out https://x.com/jc_justcharts/status/2098801213592445066?s=46
View on StockTwits ↗$SLS $MRNA $ABBV TRIED 8 Different Oral/IV/subq dosing regimes... all failed.
View on StockTwits ↗$SLS $ABBV 19 Month MOS for CR1 First Remission on BAT - is actually just 17.3 months when equalized for the time in treatment vs from Enrollment in REGAL. Any way you look at it 19 or 17 months In CR1 translates to 8 or 9 months MOS in Second Remission CR2 - just like all the doctors treating Regal patients are saying and the same as the Avalon 8.8 month MOS. https://haematologica.org/article/view/14308
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.